Table 3. Genes that promote meiotic development—enhancer of weak glp-1 gain of function.
| Genea | Product | Human homolog | Evidenceb | Reference(s) |
|---|---|---|---|---|
| Pre-mRNA splicing | ||||
| mog-1 | Yeast PRP16 related splicing factor | DHX38 | 2,4 | Belfiore et al. (2004); Kerins et al. (2010) |
| mog-4 | Yeast PRP2 related splicing factor | DHX16 | 2 | Belfiore et al. (2004); Kerins et al. (2010) |
| mog-5 | Yeast PRP22 related splicing factor | DHX8 | 2 | Belfiore et al. (2004); Kerins et al. (2010) |
| cyn-4 | cyclophilin peptidylprolyl | PPIL2 | 2,4 | Belfiore et al. (2004); Kerins et al. (2010) |
| (aka mog-6) | Isomerases | |||
| prp-17 | Yeast PRP17 related splicing factor | CDC40 | 2,4 | Kerins et al. (2010) |
| prp-19 | Yeast PRP19 related splicing factor | PRPF19 | 1 | Gutnik et al. (2018) |
| teg-1 | CD2 cytoplasmic tail-binding protein | CD2BP2 | 2,4 | Wang et al. (2012) |
| teg-4 | Splicing factor 3b subunit 3 | SF3B3 | 2,4 | Mantina et al. (2009) |
| Ubiquitin-mediated proteolysis | ||||
| pas-5 | 20S proteasome alpha-type five subunit | PSMA5 | 2,4 | Macdonald et al. (2008) |
| sel-10 | SCF E3 ubiquitin ligase | FBXW7 | 1,6 | Pepper et al. (2003a) |
| sel-11 | E3 ubiquitin ligase | SYVN1 | 1,6 | Choi et al. (2010) |
| rfp-1 | E3 ubiquitin ligase | RNF40 | 3 | Gupta et al. (2015) |
| ubr-5 | E3 ubiquitin ligase | UBR5 | 1,6 | Safdar et al. (2016) |
| RNA N6-adenosine methyltransferase | ||||
| mett-10 | Methyltransferase 10 domain containing | METTL16 | 1,2,5 | Dorsett et al. (2009) |
| Miscellaneous | ||||
| puf-8 | Pumilio RNA-binding family member | PUM1/PUM2 | 1 | Racher and Hansen (2012) |
| kin-10 | Casein kinase 2 beta | CSNK2B | 2,4 | Wang et al. (2014) |
| him-17 | THAP domain containing | — | 3 | Bessler et al. (2007) |
For all genes listed, RNAi or double mutant with weak glp-1(gf) at the permissive temperature results in a strong overproliferation phenotype.
For a gene to be included in the table, at least one additional line of experimentation (evidence 1–6, below) must be available that informs on its function in the stem cell vs. meiotic development decision. 1, RNAi or double mutant results partial or complete suppression of a glp-1(rf) at the restrictive temperature; 2, RNAi or double mutant results in a synthetic tumorous phenotype with gld-2 null and/or with gld-3 null; 3, RNAi or double mutant does not result in a synthetic tumorous phenotype with gld-2 null and/or with gld-3 null; 4, RNAi or triple mutant results in a synthetic tumorous phenotype with gld-3 null and glp-1 null; 5, RNAi or triple mutant results in a Glp-1 like phenotype with gld-3 null and glp-1 null; 6, RNAi or mutant suppresses weak lin-12 loss of function.